SecBot SecBot
25-NSE ·Filed Apr 28, 2026

ACLX

Arcellx, Inc.
BEARISH
Impact 9/10
Horizonimmediate Processed6mo ago SEC0001354457-26-000381
Notable filing: 25-NSE
Actionable Insight ▼ Bearish

Traders should expect a catastrophic gap-down at the next available trading opportunity. The stock will likely trade on OTC markets with severely reduced liquidity. Monitor for any subsequent filing regarding a potential appeal or alternative listing venue. Given the $6.7B market cap, this delisting is highly unusual and suggests a fundamental corporate event or regulatory issue not disclosed in this filing.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK AT ENTRY AT T+1
Entry
$115.07
T+0 close · Apr 28, 2026 · via day close
Latest settled
0.00%
T+1 · $115.07
Vs SPY
+0.01%
α at T+1
Next horizon
T+5
due 7mo ago
  1. T+0 · Apr 28 $115.07entry
  2. T+1 · 7mo ago 0.00%α +0.01% · $115.07
  3. T+5 · due 7mo ago Pending
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcellx, Inc. (ACLX) has been involuntarily delisted from Nasdaq, with the exchange filing a Form 25-NSE to remove the company's common stock from listing and registration under SEC Rule 12d2-2(a)(3). The delisting is effective immediately as of April 28, 2026, representing a material adverse event that removes the company's primary public trading venue.

Key Facts

  • Nasdaq Stock Market LLC filed Form 25-NSE to delist Arcellx, Inc. common stock
  • Delisting effective April 28, 2026 under SEC Rule 12d2-2(a)(3) (involuntary removal)
  • SEC File Number: 001-41259
  • Company had a market cap of $6.7B prior to delisting
  • No prior public disclosure of delisting notice or appeal in provided documents

Financial Impact

Delisting eliminates primary exchange listing for a $6.7B market cap company, likely triggering severe liquidity loss, forced selling by index funds, and potential debt covenant violations

liquiditymarket capitalizationstock pricetrading volume

Risk Factors

  • Complete loss of liquidity as stock moves to OTC markets
  • Forced selling by institutional investors and index funds that require Nasdaq listing
  • Potential debt covenant triggers or credit downgrades
  • Possible underlying corporate event (bankruptcy, fraud, regulatory action) not yet publicly disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000381
Document: 0001354457-26-000381-index-headers.html0001354457-26-000381
Document: 0001354457-26-000381-index.html0001354457-26-000381
Document: 0001354457-26-000381.txt0001354457-26-000381

Track record

3 reports on ACLX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Apr 28, 202628w ago 25-NSE Bearish 9/10 Viewing Entry $115.07 to $115.07 · 0.00% −0.01% vs SPY
  2. Apr 24, 202629w ago 10-K/A Neutral 2/10 Entry $115.07 to $115.07 · 0.00% +0.49% vs SPY
  3. Feb 25, 202637w ago Insider Cluster Bearish 7/10 Entry $113.76 to $113.88 ▼ −0.11% −0.65% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens Wed (10h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026